阿立哌唑治疗双相情感障碍的疗效和安全性：系统评价。
Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.
机构信息
Third Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
出版信息
Ann Gen Psychiatry. 2009 Jul 27;8:16. doi: 10.1186/1744-859X-8-16.
BACKGROUND
The current article is a systematic review concerning the efficacy and safety of aripiprazole in the treatment of bipolar disorder.
METHODS
A systematic Medline and repositories search concerning the usefulness of aripiprazole in bipolar disorder was performed, with the combination of the words 'aripiprazole' and 'bipolar'.
RESULTS
The search returned 184 articles and was last updated on 15 April 2009. An additional search included repositories of clinical trials and previous systematic reviews specifically in order to trace unpublished trials. There were seven placebo-controlled randomised controlled trials (RCTs), six with comparator studies and one with add-on studies. They assessed the usefulness of aripiprazole in acute mania, acute bipolar depression and during the maintenance phase in comparison to placebo, lithium or haloperidol.
CONCLUSION
Aripiprazole appears effective for the treatment and prophylaxis against mania. The data on bipolar depression are so far negative, however there is a need for further study at lower dosages. The most frequent adverse effects are extrapyramidal signs and symptoms, especially akathisia, without any significant weight gain, hyperprolactinaemia or laboratory test changes.
背景
本文是一篇关于阿立哌唑治疗双相情感障碍的疗效和安全性的系统评价。
方法
系统检索了 Medline 和文献资料库中有关阿立哌唑治疗双相情感障碍的疗效，检索词为“aripiprazole”和“bipolar”。
结果
检索到 184 篇文章，最后一次更新日期为 2009 年 4 月 15 日。此外，还对临床试验资料库和以前的系统评价进行了搜索，以追踪未发表的试验。共有 7 项安慰剂对照随机对照试验（RCT），6 项为对照研究，1 项为附加研究。它们评估了阿立哌唑在急性躁狂、急性双相抑郁以及与安慰剂、锂或氟哌啶醇相比在维持治疗阶段的疗效。
结论
阿立哌唑似乎对治疗和预防躁狂有效。目前关于双相抑郁的数据为阴性，但需要进一步在较低剂量下进行研究。最常见的不良反应是锥体外系症状，尤其是静坐不能，没有明显的体重增加、高催乳素血症或实验室检查改变。
Zotero 插件